Abstract
Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Graphical Abstract
Current Neuropharmacology
Title:Brain Structural Effects of Antidepressant Treatment in Major Depression
Volume: 13 Issue: 4
Author(s): Nicola Dusi, Stefano Barlati, Antonio Vita and Paolo Brambilla
Affiliation:
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Abstract: Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Export Options
About this article
Cite this article as:
Dusi Nicola, Barlati Stefano, Vita Antonio and Brambilla Paolo, Brain Structural Effects of Antidepressant Treatment in Major Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X1304150831121909
DOI https://dx.doi.org/10.2174/1570159X1304150831121909 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets SAMHD1 in Retroviral Restriction and Innate Immune Sensing – Should We Leash the Hound?
Current HIV Research Gas Chromatography-electron Capture Detection Method for Determination of Polyols in the Urine
Current Organic Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Protein Synthesis and Assembly in Mitochondrial Disorders
Current Topics in Medicinal Chemistry Peptides Against Autoimmune Neurodegeneration
Current Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science